Pfizer, Inc.

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:16 2024-04-18 pm EDT			After market 07:57:52 pm
25.39 ^USD	-0.12%		25.38	-0.04%

Apr. 17	Sector Update: Health Care Stocks Retreating Late Afternoon	MT
Apr. 17	Sector Update: Health Care	MT

PFIZER INC : Upgraded to Buy by UBS

December 13, 2021 at 03:48 am EST

UBS's analyst Colin Bristow raises his rating from Neutral to Buy. The target price has been lifted and is now set at USD 60 compared to USD 52 before.

Latest news about Pfizer, Inc.

Sector Update: Health Care Stocks Retreating Late Afternoon	Apr. 17	MT
Sector Update: Health Care	Apr. 17	MT
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer	Apr. 17	MT
Tara Health Foundation Files an Exempt Solicitation Statement with Securities and Exchange Commission	Apr. 16	CI
News Highlights : Top Financial Services News of the Day - Monday at 11 AM ET	Apr. 15	DJ
Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla...	Apr. 15
Novavax Shareholder Shah Capital Pushes to Add 2 Nominees to Company's Board	Apr. 15	MT
Market outlook is uncertain, but optimism prevails	Apr. 15
News Highlights : Top Financial Services News of the Day - Monday at 7 AM ET	Apr. 15	DJ
News Highlights : Top Financial Services News of the Day - Monday at 12 AM ET	Apr. 15	DJ
PFIZER INC : JP Morgan remains Neutral	Apr. 12	ZD
Skanska Trims Scope of Work for Biomanufacturing Facility Project in US	Apr. 12	MT
PFIZER INC : Berenberg remains Neutral	Apr. 10	ZD
Health Care Stocks Steady, Moderna Climbs -- Health Care Roundup	Apr. 09	DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Apr. 09	MT
Sector Update: Health Care	Apr. 09	MT
Pfizer Says Phase 3 Trial of Abrysvo for Respiratory Syncytial Virus Disease Meets Primary Endpoints	Apr. 09	MT
Pfizer's RSV Vaccine Meets Primary Endpoints in Study of Participants Under 60 Years; Seeks Expanded Access	Apr. 09	MT
Pfizer: positive results for RSV in adults	Apr. 09	CF
Pfizer's Abrysvo Hits Key Goals in Adults at Increased RSV Risk	Apr. 09	DJ
Pfizer Inc Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease	Apr. 09	CI
Pfizer RSV shot meets goals in trial of high-risk adults under age 60	Apr. 09	RE
American Airlines, Target, Others Sue Drugmakers Over Alleged Price-Fixing	Apr. 05	MT
Pfizer, Baxter, Thermo Fisher, Others FTC Cautioned to Extend Merger Review Period	Apr. 04	MT
North American Morning Briefing: Focus Turns to Jobs After Powell's Reassurance	Apr. 04	DJ

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Annual General Meeting

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 10:58 am EST

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs

October 31, 2023 at 04:50 pm EDT

More Strategies

Ratings for Pfizer, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

25.39 USD

Average target price

31.62 USD

Spread / Average Target

+24.54%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PFIZER, INC.	-11.81%	144B
ELI LILLY AND COMPANY	+27.97%	676B
NOVO NORDISK A/S	+23.58%	554B
JOHNSON & JOHNSON	-7.02%	349B
MERCK & CO., INC.	+14.85%	318B
ABBVIE INC.	+6.25%	291B
ASTRAZENECA PLC	+2.96%	210B
NOVARTIS AG	-0.41%	204B
ROCHE HOLDING AG	-10.02%	194B
AMGEN INC.	-8.80%	142B

Other Pharmaceuticals

Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

PFIZER INC : Upgraded to Buy by UBS

Latest news about Pfizer, Inc.

Chart Pfizer, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Pfizer, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals